Good news coming from the late-stage trials of an acne medication from drug giant Allergan and Paratek Pharmaceuticals. The companies are reporting that two Phase 3 trails of the drug sarecycline, an oral tetracycline-derived antibiotic with anti-inflammatory properties, has been successful in the treatment of moderate to severe acne.
David Nicholson, chief global research and development officer for Allergan says, “The positive efficacy results observed in the pivotal phase 3 clinical trials indicate that sarecycline can be an effective treatment option for patients with moderate to severe acne.” Results showed patients receiving the once-daily medication had fewer inflammatory lesions than those who didn’t. Based on the outcome of these clinical trials, Allergan has announced plans to file a new drug application for their acne medication with the Food and Drug Administration later in the year.
In addition to treating acne, sarecycline is also being evaluated for the treatment of rosacea, a condition that causes redness, bumps and blotchy skin on the face. If a daily pill can deliver clearer, healthy-looking skin, we look forward to seeing this miracle drug on the market in the near future.